Direct Healthcare Professional Communication on the safety of the medicinal product DALTRAX (abacavir, dolutegravir, lamivudine), minimizing the risk of neural tube defects

29.04.2026 Updated 04.05.2026 254 views

Information letter to health care professionals on the safe use of the medicinal product DALTRAX (abacavir, dolutegravir, lamivudine), minimizing the risk of neural tube defectsPDF · 149 KB

Завантажити

Direct Healthcare Professional Communication on the safety of the medicinal product DALTRAX (abacavir, dolutegravir, lamivudine), minimizing the risk of neural tube defects

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration

Direct Healthcare Professional Communication on the safety of the medicinal product DALTRAX (abacavir, dolutegravir, lamivudine), minimizing the risk of neural tube defects

Other materials in this section

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration